Molecular Imaging

Nuclear imaging, also called molecular imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI. Molecular imaging includes the field of nuclear medicine, which uses very small amounts of radioactive materials, or radiopharmaceuticals, to diagnose and treat disease.

Abhinav Jha to develop technique, test in patients with metastatic prostate cancer
News | Radiation Therapy
Imaging Technique May Measure Absorbed Dose from Radiation Therapy

December 22, 2022 — Patients with cancer that has spread to the bone are sometimes treated with alpha particle radiation ...

Time December 22, 2022
arrow
data showed that CytoSite’s Granzyme B (GzmB) PET imaging using [68Ga-NOTA]-hGZP (CSB-111) was feasible and safe in human subjects. These data come from a Phase I trial assessing the safety and feasibility of GzmB PET imaging in subjects with melanoma and non-small cell lung cancer (NSCLC) receiving KEYTRUDA (pembrolizumab).
News | Clinical Trials
CytoSite Bio Presents First-in-Human Data at Radiological Society of North American Annual Meeting

December 14, 2022 — CytoSite Bio, a company developing precision imaging products that determine patient response to ...

Time December 14, 2022
arrow
18F-rhPSMA-7.3 PET image showing multiple areas of uptake in the prostate gland in a man with newly diagnosed prostate cancer Photo courtesy of Blue Earth Diagnostics
News | Prostate Cancer
Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer

December 2, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time December 02, 2022
arrow
A team led by UTHealth Houston's K. Lance Gould, MD, (center) used PET imaging technology (shown above) to map coronary blood flow and its outcomes among heart disease patients. (Photo by UTHealth Houston)
News | PET Imaging
PET Technology More Effective Than Angiogram at Determining Need for Coronary Stents, Bypass Surgery

December 1, 2022 — A new method for determining whether patients with heart disease need coronary stents or bypass ...

Time December 01, 2022
arrow
Researchers at the University of Wisconsin–Madison will kick off research scanning human subjects with GE Healthcare’s latest generation PCCT prototype in December 2022, representing the first U.S. clinical evaluation site with GE Healthcare’s pure silicon CT detector technology
News | Proton Therapy
UW–Madison To Perform the First U.S. Evaluation of GE Healthcare’s Photon Counting CT Technology with Deep Silicon Detectors

November 25, 2022 — Researchers at the University of Wisconsin–Madison, the first U.S. clinical evaluation site for GE ...

Time November 25, 2022
arrow
Simulations by Rice University engineers have revealed details about the molecular interactions between gadolinium contrast agents used in MRI scans and their liquid environment. In this model, green gadolinium is surrounded by blue chelate ions, themselves surrounded by water (gray oxygen and red hydrogen atoms). Thiago Pinheiro dos Santos/Rice University
News | Magnetic Resonance Imaging (MRI)
Rice Refines Analysis of MRI Contrast Agents

November 21, 2022 — You can keep your best guesses. Engineers at Rice University’s George R. Brown School of Engineering ...

Time November 21, 2022
arrow
Figure 1. The fat pad adjacent to the kneecap (Hoffa's fat pad, infrapatellar fat pad) can change in signal on MRI when the knee is inflamed. (A) Normal knee without signs of inflammation. (B) Arrow pointing on a circumscribed area with higher signal (bright lines) in the area of the fat pad (normally dark), which is indicative of a beginning inflammatory reaction. (C) The whole fat pad has a higher signal (light grey color with white lines), which is a sign of progressive inflammation of the knee joint.
News | RSNA
NSAIDs May Worsen Arthritis Inflammation

November 21, 2022 — Taking anti-inflammatory pain relievers like ibuprofen and naproxen for osteoarthritis may worsen ...

Time November 21, 2022
arrow
NorthStar Medical Radioisotopes’ Radiopharmaceutical CDMO in Beloit, Wis. (artist rendering). Upon completion, NorthStar will be first and only U.S. company housing commercial-scale, multi-radioisotope production and radiopharmaceutical development services on the same campus, enabling collaborating companies to realize logistical, regulatory and cost benefits. (Photo: Business Wire)
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes Expands Business Platform with New, Patient-focused, Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) Services Unit

November 15, 2022 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time November 15, 2022
arrow
The American Society of Nuclear Cardiology has issued an alert about possible supply disruptions
News | Radiopharmaceuticals and Tracers
Alert: Mo-99/Tc-99m Supply Disruptions Possible

Nov. 4, 2022 — On October 28, the Nuclear Medicine Europe Emergency Response Team issued a statement about mechanical ...

Time November 05, 2022
arrow
18F-rhPSMA-7.3 PET image showing prostate cancer spread beyond the prostate region (Photo courtesy of Blue Earth Diagnostics)
News | PET Imaging
Blue Earth Diagnostics Announces Results on Clinical Factors Impacting Detection Rates from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

November 2, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time November 02, 2022
arrow
Top trends boosting the industry expansion through 2028
Feature | Contrast Media | By Shankar Khatkale
Imaging Contrast Agents Global Market Outlook

According to a recent study from market research firm Graphical Research, the global imaging agents market size is set ...

Time November 02, 2022
arrow
The oral presentation includes additional results from Blue Earth's Phase 3 SPOTLIGHT study evaluating the impact of clinical factors on the detection rate of 18F-rhPSMA-7.3 PET imaging in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy
News | PET Imaging
Blue Earth Diagnostics Highlights Presentations on Axumin (Fluciclovine F 18) and Investigational 18F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer

October 25, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 25, 2022
arrow
Company announces SCINTIX as new product name for its flagship biology-guided radiotherapy technology
News | PET-CT
RefleXion Highlights New Cancer Treatment Research Abstracts for Presentation at ASTRO 2022

October 24, 2022 — RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a ...

Time October 24, 2022
arrow
18F-SMBT-1 PET studies showed that beta-amyloid+ Alzheimer’s disease (AD) patients, but most importantly, beta-amyloid+ controls (CN) have significantly higher regional 18F-SMBT-1 binding than beta-amyloid- CN, with 18F-SMBT-1 retention highly associated with beta-amyloid burden. These findings suggest that increased 18F-SMBT-1 binding is detectable at the preclinical stages of beta-amyloid accumulation.
News | PET Imaging
Novel PET Imaging Agent Detects Earliest Signs of Alzheimer's Disease

October 20, 2022 — A new highly selective PET imaging agent can detect the presence of overexpressed monoamine oxidase-B ...

Time October 20, 2022
arrow
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the signing of a data-sharing agreement with Siemens Healthineers and the University Hospital of the Technical University of Munich (TUM) for anonymized 18F-rhPSMA-7.3 clinical data and images.
News | PET Imaging
Blue Earth Diagnostics Announces Data-sharing Agreement with Siemens Healthineers and the University Hospital of Technical University of Munich (TUM) for 18F-rhPSMA-7.3

October 19, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 19, 2022
arrow
Based on Spectrum Dynamics digital SPECT/CT platform, VERITON-CT 400 Series provides the benefits of increased sensitivity and throughput to clinical applications based on high energy isotopes used in Nuclear Medicine
News | SPECT-CT
World's First Digital SPECT/CT Capable of High Energy Imaging Enables Full Range of Clinical Capabilities to Nuclear Medicine Centers

October 18, 2022 — Spectrum Dynamics announced its newest development in digital nuclear medicine imaging: the ...

Time October 18, 2022
arrow
Mirion Technologies, Inc., a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced the appointment of Michael Rossi as the President of Mirion Medical. Michael will report directly to Mirion’s CEO, Tom Logan, who had been acting as President of the business segment.
News | Quality Assurance (QA)
Mirion Technologies Appoints Michael Rossi as President of Mirion Medical

October 7, 2022 — Mirion Technologies, Inc., a global provider of radiation detection, measurement, analysis and ...

Time October 07, 2022
arrow
The center will be equipped with a Cyclone KIUBE offering the highest production capacity with a PET cyclotron.
News | Radiopharmaceuticals and Tracers
ElsMed, Novatec and IBA Sign Contract to Install Radiopharmaceutical Production Center in Georgia

October 6, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the ...

Time October 06, 2022
arrow
Free-breathing phase-resolved functional lung (PREFUL) low-field MRI at 0.55T with calculated parameters at an axial plane after automatic registration to a mid-expiration position and lung parenchyma segmentation. From left to right, representative color-coded images of functional show ventilation defects (VDP, blue), perfusion defects (QDP, red), ventilation/perfusion (V/Q match, green), ventilation/perfusion defects (V/Q defect, purple) in a healthy control (upper row, 7-year-old male), a participant rec
Feature | Radiology Business
Top 10: September's Most-read Content

Here is a recap of what ITN viewers found most interesting during the month of September: 1. Lasting Lung Damage Seen in ...

Time October 03, 2022
arrow
News | PET Imaging
Blue Earth Diagnostics Announces FDA Acceptance of New Drug Application for 18F-rhPSMA-7.3, a Radiohybrid Prostate-Specific Membrane Antigen-Targeted PET Imaging Agent for Prostate Cancer

September 28, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time September 28, 2022
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now